To include your compound in the COVID-19 Resource Center, submit it here.

MBP8298: Phase II

In a 2-year, double-blinded Canadian Phase II trial in 32 patients, MBP8298 did not meet the primary endpoint of stabillizing clinical

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE